The price you pay for Trelegy Ellipta depends on several factors. These include your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to ...

The USA's Institute for Clinical and Economic Review (ICER) has published a special report on chronic obstructive pulmonary disease (COPD) therapies as part of the Centers for Medicare & Medicaid ...

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat patients with chronic obstructive pulmonary disease that are part of CMS's ...

European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma, denying a label extension because there was no evidence to show a reduction of flare-ups.

Fluticasone furoate, umeclidinium, vilanterol 100/62.5/25mcg, 200/62.5/25mcg; per inh; dry pwd for oral inhalation. Trelegy Ellipta is supplied as a disposable light grey and beige plastic inhaler ...

Trelegy Ellipta, a triple-therapy inhaler containing an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta-agonist (LABA), was found to offer ...

The FDA has approved GlaxoSmithKline’s Trelegy Ellipta inhaler for asthma in adults, adding to its existing use in chronic obstructive pulmonary disease (COPD), stealing a march on rivals ...

Singapore’s Health Sciences Authority (HSA) has expanded the label of GlaxoSmithKline (GSK)’s Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) to ...

The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and value of GSK Plc's (NYSE:GSK) chronic obstructive pulmonary disease (COPD) ...

TRENTON, N.J. - The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis. The FDA late Monday ...